128 related articles for article (PubMed ID: 38387803)
1. Development of a vestibular schwannoma tumor slice model for pharmacological testing.
Nickl V; Fakler J; Ziebolz D; Rumpel C; Stabenow L; Bernhagen J; Rampeltshammer E; Ernestus RI; Löhr M; Gugel I; Matthies C; Monoranu CM; Hagemann C; Breun M
J Neurosci Methods; 2024 May; 405():110082. PubMed ID: 38387803
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
Paldor I; Abbadi S; Bonne N; Ye X; Rodriguez FJ; Rowshanshad D; Itzoe M; Vigilar V; Giovannini M; Brem H; Blakeley JO; Tyler BM
J Neurooncol; 2017 Oct; 135(1):47-56. PubMed ID: 28735458
[TBL] [Abstract][Full Text] [Related]
3. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
5. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
7. Treatment of vestibular schwannoma cells with ErbB inhibitors.
Bush ML; Burns SS; Oblinger J; Davletova S; Chang LS; Welling DB; Jacob A
Otol Neurotol; 2012 Feb; 33(2):244-57. PubMed ID: 22222570
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients.
Fujii M; Ichikawa M; Iwatate K; Bakhit M; Yamada M; Kuromi Y; Sato T; Sakuma J; Saito K
Neurol Med Chir (Tokyo); 2020 Feb; 60(2):75-82. PubMed ID: 31902875
[TBL] [Abstract][Full Text] [Related]
9. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity on chromosome 22 in sporadic schwannoma and its relation to the proliferation of tumor cells.
Bian LG; Sun QF; Tirakotai W; Zhao WG; Shen JK; Luo QZ; Bertalanffy H
Chin Med J (Engl); 2005 Sep; 118(18):1517-24. PubMed ID: 16232328
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence.
Renzi S; Michaeli O; Salvador H; Alderete D; Ponce NF; Zapotocky M; Hansford JR; Malalasekera VS; Toledano H; Maguire B; Bouffet E; Ramaswamy V; Baroni LV
Pediatr Blood Cancer; 2020 May; 67(5):e28228. PubMed ID: 32124552
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Goutagny S; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
[TBL] [Abstract][Full Text] [Related]
15. Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.
Dougherty MC; Shibata SB; Clark JJ; Canady FJ; Yates CW; Hansen MR
J Neurosurg; 2023 Apr; 138(4):962-971. PubMed ID: 36087315
[TBL] [Abstract][Full Text] [Related]
16. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA
Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
[TBL] [Abstract][Full Text] [Related]
18. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
[TBL] [Abstract][Full Text] [Related]
19. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
20. A Critical Overview of Targeted Therapies for Vestibular Schwannoma.
Tamura R; Toda M
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
